

Références

- Toutes les images proviennent du site www.pixabay.com à moins d'avis contraire
- Wang Y, Du G, Du R et al. Remdesivir in adults with severe COVID-19 : a randomized, double-blind, placebo-controlled, multicentre trial. Lancet Published online April 29, 2020
- NIH Clinical trial shows remdesivir accelerates recovery from advanced COVID-19. [consulté le 2020-05-16]
- NIH protocol history. [consulté le 2020-05-19]
- Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663. doi:10.1016/j.tmaid.2020.101663
- Chen Z, Hu J, Zhang Z et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.03.22.20040758; doi:
- Tang W, Cao Z, Han M et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv 2020.04.10.20060558; doi: <https://doi.org/10.1101/2020.04.10.20060558>
- Chowdhury MS, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 [published online ahead of print, 2020 May 2]. Acad Emerg Med. 2020;10.1111/acem.14005. doi:10.1111/acem.14005
- Geleris J, Sun Y, Platt J et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. NEJM May 7 2020 DOI: 10.1056/NEJMoa2012410
- Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. Published online May 11, 2020. doi:10.1001/jama.2020.8630
- Clinical Trials. [consulté le 2020-05-16]
- Étude COLCORONA. [consulté le 2020-05-16]
- Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, Cooper Jr LT, Chahal CAA, Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management, Heart Rhythm (2020), doi: <https://doi.org/10.1016/j.jaccas.2020.04.009>.
- Dabbagh MF, Aurora L, D'Souza P, Weinmann AJ, Bhargava P, Basir MB, Cardiac Tamponade Secondary to COVID-19, JACC Case Reports (2020), doi: <https://doi.org/10.1016/j.jaccas.2020.04.009>.
- Doyen D, Mocerri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet 2020 DOI [https://doi.org/10.1016/S0140-6736\(20\)30912-0](https://doi.org/10.1016/S0140-6736(20)30912-0)
- Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1017

Références

- Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. *Drugs* (2017) 77:1865–1879
- Martin Sheppard, Faidra Laskou, Philip P. Stapleton, Shahryar Hadavi & Bhaskar Dasgupta (2017) Tocilizumab (Actemra), *Human Vaccines & Immunotherapeutics*, 13:9, 1972-1988, DOI: 10.1080/21645515.2017.1316909
- Luo P1, Liu Y1, Qiu L1, Liu X1, Liu D1, Li J1. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol*. 2020 Apr 6. doi: 10.1002/jmv.25801. [Epub ahead of print]
- Klopfenstein T, Zayet S, Lohse A, Balblanc J-Charles, Badie J, Royer P-Yves, Toko L, Mezher C, Kadiane-Oussou NJ, Bossert M, Bozgan A-Maria, Charpentier A, Roux M-Françoise, Contreras R, Mazurier I, Dussert P, Gendrin V, Conrozier T, Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients, *Médecine et Maladies Infectieuses* (2020), doi: <https://doi.org/10.1016/j.medmal.2020.05.001>
- Tocilizumab sur [consulté le 2020-05-16]
- Veronese N, Demurtas J, Yang L, et al. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. *Front Med (Lausanne)*. 2020;7:170. Published 2020 Apr 24. doi:10.3389/fmed.2020.00170
- Li H1,2, Chen C2,3, Hu F1, Wang J4, Zhao Q2, Gale RP5, Liang Y6. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. *Leukemia*. 2020 May 5. doi: 10.1038/s41375-020-0848-3. [Epub ahead of print]
- Fadel R, Morrison A, Vahia A, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Published online May 5, 2020. doi:10.1101/2020.05.04.20074609
- Attaway A1. Management of patients with COPD during the COVID-19 pandemic. *Cleve Clin J Med*. 2020 May 11. pii: ccc007. doi: 10.3949/ccjm.87a.ccc007. [Epub ahead of print]
- Tal-Singer R1, Crapo JD2,3. COPD at the Time of COVID-19: A COPD Foundation Perspective. *Chronic Obstr Pulm Dis*. 2020 Apr;7(2):73-75. doi: 10.15326/jcopdf.7.2.2020.0149.
- GOLD Initiative COVID-19 guidance <https://goldcopd.org/gold-covid-19-guidance/>
- Kumar K1, Hinks TS2, Singanayagam A1. Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used? *Am J Physiol Lung Cell Mol Physiol*. 2020 May 13. doi: 10.1152/ajplung.00144.2020. [Epub ahead of print]
- Akenroye AT, Wood R, Keet C, Asthma, Biologics, Corticosteroids, and COVID-19, *Annals of Allergy, Asthma and Immunology* (2020), doi: <https://doi.org/10.1016/j.anai.2020.05.001>.
- Guwartz G Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics *Drug Dev Res*. 2020;1–4.
- Vaduganathan M1, Vardeny O1, Michel T1, McMurray JJV1, Pfeffer MA1, Solomon SD1. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
- Sommerstein R1, Kochen MM2, Messerli FH3,4,5, Gräni C3. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? *J Am Heart Assoc*. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.

Références

- Mehta N, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. Published online May 05, 2020. doi:10.1001/jamacardio.2020.1855
- Mehra MR1, Desai SS1, Kuy S1, Henry TD1, Patel AN1. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med*. 2020 May 1. doi: 10.1056/NEJMoa2007621. [Epub ahead of print]
- Stratton L, Berlin DA, Arbo JE. Vasopressors and inotropes in sepsis. *Emerg Med Clin N Am* 2017;35:75-91.
- Jentzer JC, Coons JC, Link CB et al. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. *J Cardiovasc Pharmacol Ther* 2015 May;20(3):249-60.
- Thompson R, Patel P. Treatment of haemodynamic disturbance. *Br J Hosp Med (Lond)* 2017;78(5):C78-C80.
- Lange M, Van Aken H, Westphal M et al. Role of vasopressinergic V1 receptor agonists in the treatment of perioperative catecholamine-refractory arterial hypotension. *Best Pract Res Clin Anesthesiol* 2008 Jun;22(2):369-81
- SCCM. Ligne directrice de la SCCM sur la prise en charge des patients atteints de la COVID-19. [consulté le 2020-05-16]
- Onwochei DN, Kee WD, Fung L et al. Norepinephrine intermittent intravenous boluses to prevent hypotension during spinal anesthesia for cesarean delivery : a sequential allocation dose-finding study. *Anesth Analg* 2017;125:212-8.
- Holden D, Ramich J, Timm E et al. Safety considerations and guideline-based safe use recommendations for «bolus-dose» vasopressors in the emergency department. *Ann Emerg Med* 2018;71:83-92.
- Kee WDN. A random-allocation graded dose-response study of norepinephrine and phenylephrine for treating hypotension during spinal anesthesia for cesarean delivery. *Anesthesiology* 2017;127:934-41.
- Gottlieb M. Bolus-dose of epinephrine for refractory post-arrest hypotension. *CJEM* 2017:1-5.
- Rotella JA, Zarei F, Frauman AG et al. Refractory hypotension treated with vasopressin after intentional clozapine. *Eur J Emerg Med* 2014;21:319-322 *J Cardiothorac Vasc Anesth* 2010 Jun;24(3):467-8.
- Barr J et coll. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med* 2013 Jan;41(1):263-306.
- Reade MC et Finfer S. Sedation and delirium in the intensive care unit. *N Engl J med* 2014Jan30;370(5):444-54.
- Devlin JW, Skrobik Y, Gélinas C et coll. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. *Crit Care Med*. 2018 Sep;46(9):e825-e873.
- Hoy SM et Keating GM. Dexmedetomidine. *Drugs* 2011;71(11):1481-1501.
- Mcmillian WD, Taylor S et Lat I. Sedation, analgesia, and delirium in the critically ill patient. *J Pharm Pract* 2011Feb;24(1):27-34.